Surgery for a one-eye surface tumor in people with HIV
Part of Cancer, Eyes & vision, Infections clinical trials.
This study looks at whether removing a suspected pre-cancer/cancer growth on the surface of the eye can be done safely in people living with HIV. It is a feasibility (safety and practical) study, helping doctors refine the best surgical approach and follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a suspected OSSN (ocular surface squamous neoplasia) growth in only one eye
- A study eye specialist must confirm the growth can be removed with small safety margins and without affecting key inner eye surface areas
- You are living with HIV and can show proof of HIV testing or treatment (ART) within required documentation rules
- You should be well enough to do daily activities (WHO performance status 0–2)
- You should not have had other investigational medicines in the last 30 days (ART trial meds allowed)
- You should not have certain past eye growths (like prior OSSN or other eye cancers) and should not have uncontrolled medical problems or issues that would stop follow-up
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a “sentinel lymph node biopsy” can better detect cancer spread in people with specific cancers of the eye surface and nearby tissues. It may help doctors find the right next treatment by learning whether lymph nodes are involved.
This trial is testing new treatments for cryptococcal meningitis, a serious brain infection, in people living with HIV. It aims to find the best way to treat this infection with fewer side effects.
This trial tests an HPV vaccine in people living with HIV to see if it is safe and helps their immune system fight HPV. HPV can cause certain cancers, and this study hopes to protect people with HIV who are more at risk.
This study compares different ways to screen for cervical cancer in women living with HIV. It aims to find the most effective and practical screening approach for this group.
This trial tests a gel called ACU-D1 for treating high-grade precancerous lesions caused by HPV in the vulvar or perianal area. The goal is to see if the gel can help clear these lesions in people living with HIV.
This study tests if a probiotic called EXE-346 can help clear anal high-grade squamous intraepithelial lesions (HSIL), a precancerous condition, in people with HIV who are on effective antiretroviral therapy. If you have anal HSIL that wasn't fully removed by biopsy, you may be able to join.
Hear when a new HPV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.